WT1 Expression in Peripheral Blood at Diagnosis and During the Course of Early Consolidation Treatment Correlates With Survival in Patients With Intermediate and Poor-Risk Acute Myeloid Leukemia

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F20%3A10418633" target="_blank" >RIV/00216208:11110/20:10418633 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00023736:_____/20:00013103

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=2r7cKlZjBh" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=2r7cKlZjBh</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.clml.2020.07.014" target="_blank" >10.1016/j.clml.2020.07.014</a>

Jazyk výsledku

angličtina

Název v původním jazyce

WT1 Expression in Peripheral Blood at Diagnosis and During the Course of Early Consolidation Treatment Correlates With Survival in Patients With Intermediate and Poor-Risk Acute Myeloid Leukemia

Popis výsledku v původním jazyce

Dynamics of WT1 expression during the course of chemotherapy was tested in 106 cases of intermediate and high-risk acute myeloid leukemia in peripheral blood. High WT1 expression after 2 cycles of chemotherapy was a significant prognostic factor for overall and event-free survival in the whole cohort, as well as in patients treated without allogeneic stem cell transplantation. Background: Up to 55% of non-APL acute myeloid leukemias (AML) lack a molecular target suitable for standardized disease monitoring. We aimed to evaluate the prognostic significance of WT1 gene expression at early stages of intensive treatment. Patients and Methods: A total of 10(6) consecutive patients with intermediate and high-risk AML who had WT1 expression at diagnosis &gt;500 copies/10(4) ABL and who achieved remission after 1 to 2 cycles of induction treatment were analyzed. WT1 expression was measured in peripheral blood using a standardized European LeukemiaNet method. Overexpression was defined as &gt;50 copies/10(4) ABL. The median follow-up was 30 months. Results: Patients with normal versus high WT1 expression after 2 cycles of chemotherapy had overall survival (OS) at 3 years of 66% versus 41% (P=.01); event-free survival (EFS) 45% versus 22% (P=.01). Prognostic significance of WT1 expression after 2 cycles of treatment was maintained in the group of patients treated with chemotherapy alone without hematopoietic stem cell transplantation in first line treatment (OS 70% vs. 36%, P=.02; EFS 35% vs. 0%, P=.03). Significant prognostic factors for EFS on multivariate analysis were the achievement of molecular remission (&lt;50 copies of WT1) at any time during treatment (hazard ratio [HR] 0.47, P=.04) and increased WT1 expression after 2 cycles of chemotherapy (HR 2.0, P=.03). Conclusion: Increased WT1 expression after 2 cycles of chemotherapy is a negative prognostic factor for survival. WT1 remains a valuable molecular marker in AML without any leukemiaspecific mutation, especially if next generation sequencing and/or digital polymerase chain reaction are not routinely available.

Název v anglickém jazyce

WT1 Expression in Peripheral Blood at Diagnosis and During the Course of Early Consolidation Treatment Correlates With Survival in Patients With Intermediate and Poor-Risk Acute Myeloid Leukemia

Popis výsledku anglicky

Dynamics of WT1 expression during the course of chemotherapy was tested in 106 cases of intermediate and high-risk acute myeloid leukemia in peripheral blood. High WT1 expression after 2 cycles of chemotherapy was a significant prognostic factor for overall and event-free survival in the whole cohort, as well as in patients treated without allogeneic stem cell transplantation. Background: Up to 55% of non-APL acute myeloid leukemias (AML) lack a molecular target suitable for standardized disease monitoring. We aimed to evaluate the prognostic significance of WT1 gene expression at early stages of intensive treatment. Patients and Methods: A total of 10(6) consecutive patients with intermediate and high-risk AML who had WT1 expression at diagnosis &gt;500 copies/10(4) ABL and who achieved remission after 1 to 2 cycles of induction treatment were analyzed. WT1 expression was measured in peripheral blood using a standardized European LeukemiaNet method. Overexpression was defined as &gt;50 copies/10(4) ABL. The median follow-up was 30 months. Results: Patients with normal versus high WT1 expression after 2 cycles of chemotherapy had overall survival (OS) at 3 years of 66% versus 41% (P=.01); event-free survival (EFS) 45% versus 22% (P=.01). Prognostic significance of WT1 expression after 2 cycles of treatment was maintained in the group of patients treated with chemotherapy alone without hematopoietic stem cell transplantation in first line treatment (OS 70% vs. 36%, P=.02; EFS 35% vs. 0%, P=.03). Significant prognostic factors for EFS on multivariate analysis were the achievement of molecular remission (&lt;50 copies of WT1) at any time during treatment (hazard ratio [HR] 0.47, P=.04) and increased WT1 expression after 2 cycles of chemotherapy (HR 2.0, P=.03). Conclusion: Increased WT1 expression after 2 cycles of chemotherapy is a negative prognostic factor for survival. WT1 remains a valuable molecular marker in AML without any leukemiaspecific mutation, especially if next generation sequencing and/or digital polymerase chain reaction are not routinely available.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical Lymphoma, Myeloma &amp; Leukemia

ISSN

2152-2650

e-ISSN

—

Svazek periodika

20

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

12

Strana od-do

"e998"-"e1009"

Kód UT WoS článku

000593321200009

EID výsledku v databázi Scopus

2-s2.0-85090066450